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Background: Cetuximab (chimeric monoclonal antibody to human epidermal growth factor re-
ceptor) is used to treat colorectal and head and neck cancers. Due to cross-reactivity with galac-
tose-a-1,3-galactose (alpha-gal), it can induce hypersensitivity even at first administration. We
aimed to determine the incidence and clinical manifestation of cetuximab-induced anaphylaxis,
and to establish a means of predicting its incidence in patients ahead of treatment.
Methods: Nationwide and single-center pharmacovigilance data from 2010 to 2017 were
collected from the Korea Institute of Drug Safety-Korea Adverse Event Reporting System and
Severance Regional Pharmacovigilance Center. Patients scheduled for cetuximab administration
were enrolled prospectively. A skin prick test was carried out and serum IgE specific to cetuximab
and cross-reactive allergens were measured. Reactions were monitored after cetuximab infusion.
Results: Over 8 years, there were 23 reports of anaphylaxis nationwide. In a single-center study,
incidence of cetuximab-induced anaphylaxis was 1.1%. Most anaphylaxis occurred at first injection
(93.3%), even under pretreatment with anti-allergic drugs. Four of 64 patients (6.3%) experienced
severe anaphylaxis. The median cetuximab-specific IgE titer was 6.9 kUA/L in patients experiencing
anaphylaxis and 0 kUA/L in those who did not (P < 0.001). The results of alpha-gal, beef sIgE, and
cetuximab skin prick testing were similar to those of cetuximab sIgE. Patients who did not expe-
rience hypersensitivity were negative in all 4 allergy tests. Its positive and negative predictive
values were 100%.
Conclusions: Specific IgE detection of cetuximab or alpha-gal can accurately predict cetuximab-
induced anaphylaxis prior to first administration.
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Cetuximab is a chimeric anti-epidermal growth
factor receptor IgG1 antibody used to treat meta-
static colorectal cancer and head and neck can-
cers, derived from human (70%) and mouse (30%)
sources.1 Biological monoclonal antibodies such
as cetuximab can induce acute infusion reaction,
also known as cytokine release syndrome.2 In
addition, the presence of specific IgE (sIgE) to
galactose-a-1,3-galactose induced by natural
exposure can elicit cetuximab-induced anaphylaxis
at first exposure;3 severe hypersensitivity reactions
(HSR), which may be life threatening, occur in 3%
of cetuximab recipients.4–6 Due to their similar
symptoms and time of onset, it can be difficult to
distinguish between cytokine release syndrome
and IgE-mediated HSR. Since the two have
different mechanisms, prediction of anaphylaxis by
identifying sIgE would be useful in developing
effective treatment plans.
Previous predictive studies have used laboratory
methods such as enzyme-linked immunosorbent
assay (ELISA), but this has limitations in real clinical
situations. We analyzed the nationwide prevalence
of adverse reactions to cetuximab, and investi-
gated means of predicting cetuximab-related
anaphylaxis prior to first exposure using clinical
methods contrast to laboratory-based methods.METHODS
Nationwide and single-center pharmacovigilance
data collection
Pharmacovigilance data on cetuximab were
collected from the Korea Institute of Drug Safety-
Korea Adverse Event Reporting System (KIDS-
KAERS) database of the Korea Institute of
Drug Safety and Risk Management. This system
consists of 27 regional pharmacovigilance
centers in Korea7 including Severance Hospital in
Seoul. Adverse drug reaction (ADR) reports from
2010 to 2017 were thoroughly reviewed. Adverse
reactions were reported according to World
Health Organization-Adverse Reaction Terminol-
ogy (WHO-ART), including date, age, gender, re-
porter, clinical manifestations, severity, progress,
responses to re-administration, and causality.
Causal relationships were assessed using World
Health Organization-Uppsala Monitoring Center(WHO-UMC) criteria from unlikely to certain. To
overcome limitations of the self-reported anony-
mized ADR database, ADRs assessed to have
stronger relationship (certain and probable/likely)
between exposure and outcome was selected.
ADRs reporting cetuximab as a concomitant drug
only were excluded from the analysis.
To obtain more specific clinical information
(number of infusion, primary cancer, underlying
diseases, and progress of ADR), we also collected
data from the Severance Hospital Regional Phar-
macovigilance Center operated by Yonsei Univer-
sity in Seoul, Korea. This is a well-established
pharmacovigilance center with the assistance of
the government and tertiary teaching hospital,
which was established in 1990. In 2019, there were
10,322 ADR reports. ADR reports from the period
2010 to 2017 were analyzed in conjunction with
reports from KIDS-KAERS and the single pharma-
covigilance center. Anaphylaxis was defined as
systemic severe allergy during hypersensitivity ac-
cording to World Allergy Organization (WAO)
diagnostic criteria.8Predictive model subjects
A prospective observational study was designed
to predict cetuximab-induced anaphylaxis, based
on an allergy prediction model to detect sIgE prior
to first administration in patients with colorectal
and head and neck cancers. Patients over 18 years
of age who were scheduled for cetuximab treat-
ment according to standard guidelines were
enrolled based on the judgment of the oncologist
participating in the study. This study was approved
by the Institutional Review Board of the Yonsei
University Health System (No. 4-2016-0811) and
registered at the clinical trial database (clinical-
trials.gov NCT03485638). Patients who did not
voluntarily consent to the study or who did not
complete the written consent form were excluded.
Cetuximab sIgE reactivity was checked using
in vivo and in vitro methods, including a skin prick
test (SPT), enzyme-linked immunosorbent (ELISA)
assay, and ImmunoCAP (Phadia 250, Thermo-
Fisher Scientific, Waltham, USA) assay. Past history,
including allergy, was reviewed prior to SPT to
cetuximab. After SPT, a 5 mL blood sample was
obtained for serum IgE testing, and patients were
given antihistamine and systemic corticosteroid as
Volume 14, No. 7, Month 2021 3premedication. Cetuximab was infused a 1–2 h
period according to body surface area, while pa-
tients were admitted or during outpatient chemo-
therapy injection. After confirming safe
administration of cetuximab, subsequent anti-
cancer drugs were administered. Adverse re-
actions were closely monitored during the
chemotherapy by expert nurses. The study scheme
is shown in Fig. 1.
Detection of specific immunoglobulin E against
cetuximab
For SPT, 5 mg/mL cetuximab (Erbitux, Merck,
Darmstadt, Germany) was used. Normal saline with
0.3% phenol and 50% glycerol was used as a
negative control, and 0.1% histamine (Allergy
Therapeutics, Worthing, UK) was used as a positive
control. Prior to SPT, all participants were asked to
discontinue medications that might influence the
results. If the drugs could not be stopped or
changed for SPT, the subjects conducted the
in vitro test except SPT. SPT results were recorded
and interpreted by an allergy specialist clinical
research nurse. Wheals and erythema were
measured 15 min after pricking; wheal sizes of
3 mm were considered positive reactions. No
intradermal test was performed.
ELISA and ImmunoCAP assay were used to
detect serum sIgE to cetuximab. For ELISA, a
microplate was coated with cetuximab (2 m/L;
Erbitux, Merck, Darmstadt, Germany) in 0.05 M
carbonate buffer (pH 9.6) overnight at 4 C. After









Fig. 1 Study schemephosphate buffered saline with Tween 20, serum
samples (diluted 1:4) were added and the plate
was incubated for 1 h. Biotinylated goat anti-
human IgE (1:1000; Vector, Burlingame, CA, USA)
was added to each well and incubated with
streptavidin (1:1000; Sigma-Aldrich) for 30 min.
The colorimetric reaction was developed using
3,30,5,50-tetramethylbenzidine (Kirkegaard & Perry
Laboratories, Gaithersburg, MD, USA). After stop-
ping the enzyme reaction by adding 0.5 M H2SO4,
absorbance was measured at 450 nm. The cutoff
value was determined as the mean absorbance
plus twice the standard deviation obtained from
the normal controls.
At present, there are no commercial kits for
direct measurement of cetuximab sIgE by Immu-
noCAP. Alpha-gal (ImmunoCAP code o215, from
bovine thyroglobulin source material) and beef
(ImmunoCAP code f27, from raw meat source
material) IgE, which cross-react with cetuximab3
were measured first, on the same or subsequent
day as blood samples were collected.
To detect cetuximab sIgE using ImmunoCAP,
cetuximab was biotinylated using EZ-Link Sulfo-
NHS-LC-Biotin (ThermoFisher Scientific, Waltham,
USA). Biotinylated cetuximab diluted 1:9 in PBS
was immobilized on a streptavidin CAP microplate.
We then used the ImmunoCAP system with a
sensitivity range of 0.1 kUA/L to 100 kUA/L; sIgE
concentrations 0.35 kUA/L were considered
positive.
Statistical analysis
We used IBM SPSS Statistics for Windows
version 23.0 (IBM Corp Armonk, NY) for data
analysis. Nonparametric continuous data were
analyzed using a Mann-Whitney U test, and cate-
gorical data were analyzed using Fisher’s exact or
Pearson’s chi-squared tests. A P value of <0.05 was
considered significant.RESULTS
Nationwide pharmacovigilance reports on
cetuximab (n ¼ 369)
Nationwide pharmacovigilance data for cetux-
imab across the 8 years surveyed indicated that
the most common ADRs were cutaneous mani-
festations, including rash (53.7%), pruritus (33.9%),
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old. Male patients were twice as many as female
patients. Fifty patients experienced serious re-
actions, including life-threatening ADRs, necessity
or extension of hospitalization, and important
medical issues (specific information could not beSelf-reported ADRs to cetuximab in Korea (N ¼ 369






































Table 1. Nationwide pharmacovigilance data on cetuximab over 8 yea
Organization-Uppsala Monitoring Centerchecked due to database characteristics). There
was no death or significant disability caused by
cetuximab ADR. Among the 369 patients, 23 pa-
tients (6.2%) suffered from anaphylaxis induced by





























rs in Korea. ADR, adverse drug reaction; WHO-UMC, World Health
Fig. 2 Number of cetuximab prescription over time
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There were 1268 patients treated with cetuximab
over 9551 infusions during the period of study
(Fig. 2). During this time, the number of patients
treated with cetuximab increased, but the
incidence of anaphylaxis did not increase (data
not shown). A total of 15 patients suffered from
anaphylaxis, at a rate of 1.2%, in spite of preventive
antihistamine and systemic steroid drugs. In these
cases, anaphylaxis usually developed at first dose of
cetuximab (13/15, 86.7%). One patient underwent
cardiopulmonary resuscitation but recovered
without complication. Because of these unexpected
ADRs, 9 out of 15 (60%) anaphylactic patients
changed or gave up on the first line treatment. Two
patients were able to continue the use of cetuximab
after desensitization.
Predictive model (n ¼ 64)
Among patients who visited the oncology
department, 109 who were scheduled for first
administration of cetuximab were screened. Since
the screening subjects were first diagnosed with
stage IV cancer and planned for their first chemo-
therapy, 39.4% of the participation refused to
participated to the prospective observational al-
lergy prediction study. After exclusions were
applied, 64 adult patients with stage IV colorectal
cancers were included (Table 2).Four patients (6.3%) who received cetuximab
experienced anaphylaxis despite the use of anti-
allergic premedication. These patients were 18
years older than the control group (P ¼ 0.012), but
there was no difference in history of allergic dis-
eases, blood tests, whether to use anti-allergic
premedication, or the type of anticancer drugs
administered in concert. In both groups, the pro-
portion of male patients was high, and 3 out of 4
who developed anaphylaxis were male.
Anti-cetuximab sIgE and anaphylaxis
ImmunoCAP assay indicated significantly higher
concentration of sIgE to cetuximab (Fig. 3A),
alpha-gal (Fig. 3B), and beef (Fig. 3C) in patients
experiencing anaphylaxis (P < 0.001). The
median and range values were shown in Table 2.
Based on the 0.35 kUA/L positive cut-off, all of
the sensitivity, specificity, and positive predictive
values, and negative predictive values of beef,
alpha-gal, and cetuximab were 100%. Although
there was no difference in positive and negative
predictive values for each sIgE antigen measured,
cetuximab and alpha-gal sIgE concentrations were
significantly higher than beef sIgE (P ¼ 0.043).
Optical density detected using ELISA also
showed significant differences between patients
who experienced anaphylaxis and those who did
not (Fig. 3D, P < 0.001). Of the 62 patients who
No Anaphylaxis (N ¼ 60) Anaphylaxis (N ¼ 4) P value
Age in years, median (range) 55.5 (30–80) 73.5 (57–76) 0.012
Gender, N (%) >0.999
Male 38 (63.3) 3 (75)
Female 22 (36.7) 1 (25)
Allergy History, N (%)
Asthma 1 (1.7) 0 (0) >0.999
Food allergy 0 (0) 0 (0)
Drug allergy (any) 1 (1.7) 0 (0) >0.999
Laboratory findings in median (range)
Eosinophil (numbers/mL) 145 (0–900) 205 (90–2,088) 0.227
AST (IU/L) 20.5 (7–166) 22 (21–32) 0.428
ALT (IU/L) 20 (6–138) 16.5 (6–22) 0.285
BUN (mg/dL) 12.5 (4.5–31.0) 14.8 (13.6–22.1) 0.367
Creatinine (mg/dL) 0.8 (0.3–1.4) 0.9 (0.7–0.9) 0.718
EGFR (ml/min/1.73 m2) >90 (52->90) 87 (61->90) 0.353
Allergy serum test (positive ratio)
Cetuximab sIgE 0/60 (0%) 4/4 (100%) < 0.001
Cetuximab sIgE 0/60 (0%) 4/4 (100%) < 0.001
Alpha-gal sIgE 0/60 (0%) 4/4 (100%) < 0.001
Beef sIgE 0/60 (0%) 4/4 (100%) < 0.001
Allergy skin test (positive ratio)
Cetuximab SPT 0/60 (0%) 2/2 (100%) < 0.001
Premedication, N (%)
Anti-histamine 60 (100) 4 (100)
Corticosteroid 60 (100) 4 (100)
Combination therapy, N (%) 0.502
Irinotecan 2 (3.3) 0 (0)
Fluorouracil and Irinotecan 51 (85.0) 3 (75)
Fluorouracil and Oxaliplatin 7 (11.7) 1 (25)
Table 2. Baseline characteristics of patients included in predictive modeling analysis. EGFR, estimated glomerular filtration rate; sIgE, specific
immunoglobulin E; O.D, optical density measured by ELISA; SPT, skin prick test; Gender, allergy history, cetuximab SPT, and combination therapy were
analyzed using Fisher’s exact test. Age, laboratory findings, and sIgEs were analyzed using a Mann-Whitney U test. Values with a P value less than 0.05 are
displayed in bold.
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showed anaphylactic reaction at cetuximab first
administration.Characteristics of cetuximab-induced anaphylaxis
When anaphylaxis occurred, it did so an average
of 17 min after cetuximab administration (Table 3).
All affected patients suffered hypotension,
respiratory difficulty, and change in mental status.
Three patients (75%) were needed intramuscular
epinephrine to treat anaphylaxis. Despite these
severe reactions, there were no casualties. All ofthe anaphylactic patients stopped the use of
cetuximab and changed the chemotherapy agent.
None of the anaphylactic patients had food allergy
especially to the red meat.DISCUSSION
This study synthesizes comprehensive data on
cetuximab-induced ADRs over an 8-year period,
and helps to shed light on IgE-mediated HSR to
versus cytokine release syndrome. Both in vivo
(SPT) and in vitro (serum sIgE: ImmunoCAP, ELISA)
Fig. 3 Comparison of cetuximab specific IgE responses between groups
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predictive power.
Each test method has its own advantages and
disadvantages. SPT results can be interpreted
within 15 min, but a commercial cetuximab SPT
reagent is not available, and an accurate test
requires the interruption of drugs which can affect
its outcome, including antihistamine, systemic
steroids, and antidepressants. Meanwhile, both
ELISA and ImmunoCAP assays were predictive of
anaphylaxis. ImmunoCAP in particular can reduce
the required incubation time for antigens and an-
tibodies, and is automated to minimize technical
errors; it is also the gold standard sIgE quantitation
assay recommended by the World Health Orga-
nization. Quantitative sIgE titer can be reported in
about 7 h using the ImmunoCAP (Phadia 250
version). Alpha-gal (and cross-reactive cetuximab)
is component antigens that induce severe allergic
reaction among beef antigens. In our study, sIgE
concentration was higher in the component anti-
gens compared to crude beef allergen. In aNo Age Gender Onset
1 76 M 1 min Shock, Dysp
2 57 F 20 min Shock, Dysp
3 73 M 15 min Shock, Dysp
4 74 M 13 min Shock, Whee
Table 3. Clinical manifestations of anaphylactic patientsmedical setting when the limited allergens can be
selected for diagnosis, it may be more helpful to
measure the sIgE of the component allergen.
When IgE-mediated HSR is confirmed, safe
exposure can be established through either
desensitization or graded challenge.9 Successful
desensitization of patients who experienced
cetuximab-induced anaphylaxis has been re-
ported.10,11 Advance prediction of HSR risk can
help enable safe adherence to first-line cancer
treatment, and improve treatment outcomes and
quality of life in advanced cancer patients. Pre-
diction can also reduce unnecessary medical costs.
Although products for cetuximab sIgE measure-
ment are not yet available, alpha-gal sIgE mea-
surement was similarly predictive and ready for
immediate clinical application. In addition, though
we aimed to predict HSR prior to first exposure,
our findings can be also be used to observe sIgE
generated during the course of treatment due to
repeated exposures. This early diagnosis of HSRClinical manifestations
nea, Syncope
nea, Drowsy mental status, Urticaria, Nausea
nea, Drowsy mental status, Vomiting, Nausea
zing, Stupor mental status, Urination, Defecation
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severe hypersensitivity.
The results of the present study correspond well
with those found in the previous studies. Predic-
tion studies were performed using cetuximab sIgE
by ELISA method,12–15 and basophil activation
testing.13 An additional study detected alpha-gal
sIgE using ImmunoCAP assay with a custom pro-
tein not yet approved for diagnostic use by the US
Food and Drug Administration, which found that
patients who tested negative for alpha-gal sIgE did
not develop anaphylaxis (n ¼ 37).16 Retrospective
trials to detect cetuximab sIgE using ImmunoCAP
using products on development,17 and ELISA
have also been carried out.18
Atopy status, age, gender, race, concomitant
therapy, and primary cancer site have been pro-
posed as risk factors for cetuximab-induced
anaphylaxis, but these hypotheses are unre-
solved.19 Our findings did not indicate significant
differences between compared groups, except
for age and sIgE reactivity.
Some additional research will need to be carried
out to verify our interpretations, due to key study
limitations. First, prevalence of cetuximab-related
HSR can vary by geographic distribution4,20 and
our entire test subject was Korean. It is known that
alpha-gal sensitization is caused by a lone star
tick,21 but since there is no such tick in Korea, it is
presumed that sensitization was preceded by
other mechanisms. Second, cetuximab-related
HSR is reported to occur at higher incidence in
patients with head and neck cancer compared to
those with colorectal cancer,22,23 who made up our
study population. Third, only a limited number of
patients agreed to SPT. Non-irritating concentra-
tion was not defined due to the limitations of testing
of anti-cancer drugs in healthy patients. However, 2
patients who were allergic to cetuximab reacted to
5 mg/mL of cetuximab at SPT.
There are fewer studies on alpha-gal syndrome
in Asian countries than in western countries. One
Korean alpha-gal syndrome patient in an earlier
study experienced cetuximab-induced anaphylaxis
at first exposure.24 However, none of the
cetuximab-allergic patients enrolled in this study
experienced an allergic reaction after eating red
meat. Further research on alpha-gal syndrome inAsia may shed light on risk factors and mecha-
nisms of cetuximab-induced HSR.
In conclusion, automated quantitative sIgE
detection of alpha-gal or cetuximab can be helpful
to predict cetuximab-induced anaphylaxis prior to
its first administration, allowing for safe clinical
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